With current economic pressures and tightening market conditions for life sciences companies, it is more important than ever to arm customer-facing teams – sales, marketing, medical science
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh